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A B S T R A C T
α-synuclein (αS) is a small protein that self-aggregates into α-helical oligomer species and subsequently into
larger insoluble amyloid ﬁbrils that accumulate in intraneuronal inclusions during the development of
Parkinson's disease. Toxicity of αS oligomers and ﬁbrils has been long debated and more recent data are sug-
gesting that both species can induce neurodegeneration. However while most of these data are based on dif-
ferences in structure between oligomer and aggregates, often preassembled in vitro, the in vivo situation might be
more complex and subcellular locations where αS species accumulate, rather than their conformation, might
contribute to enhanced toxicity. In line with this observation, we have shown that αS oligomers and aggregates
are associated with the endoplasmic reticulum/microsomes (ER/M) membrane in vivo and how accumulation of
soluble αS oligomers at the ER/M level precedes neuronal degeneration in a mouse model of α-synucleino-
pathies. In this paper we took a further step, investigating the biochemical and functional features of αS species
associated with the ER/M membrane. We found that by comparison with non-microsomal associated αS (P10),
the ER/M-associated αS pool is a unique population of oligomers and aggregates with speciﬁc biochemical traits
such as increased aggregation, N- and C-terminal truncations and phosphorylation at serine 129. Moreover,
when administered to murine primary neurons, ER/M-associated αS species isolated from diseased A53T human
αS transgenic mice induced neuronal changes in a time- and dose-dependent manner. In fact the addition of
small amounts of ER/M-associated αS species from diseased mice to primary cultures induced the formation of
beads-like structures or strings of ﬁbrous αS aggregates along the neurites, occasionally covering the entire
process or localizing at the soma level. By comparison treatment with P10 fractions from the same diseased mice
resulted in the formation of scarce and small puncta only when administered at high amount. Moreover, in-
creasing the amount of P100/M fractions obtained from diseased and, more surprisingly, from presymptomatic
mice induced a signiﬁcant level of neuronal death that was prevented when neurons were treated with ER/M
fractions immunodepleted of αS high molecular weight (HMW) species. These data provide the ﬁrst evidence of
the existence of two diﬀerent populations of αS HMW species in vivo, putting the spotlight on the association to
ER/M membrane as a necessary step for the acquisition of αS toxic features.
1. Introduction
Accumulation of α-synuclein (αS) aggregates in intracellular pro-
teinacious inclusions called Lewy Bodies (LB) or Lewy neurites, ac-
cording to their subcellular location, is a classical hallmark of
Parkinson's disease (PD) and α-synucleinopathies (Goedert et al.,
2012). αS is a small, soluble acidic protein highly expressed throughout
the nervous system and with a well-described presynaptic localization
(Iwai et al., 1995; Maroteaux et al., 1988). Point mutations in the αS
gene (Appel-Cresswell et al., 2013; Krüger et al., 1998; Lesage et al.,
2013; Polymeropoulos et al., 1997; Zarranz et al., 2004) and gene
ampliﬁcations (Chartier-Harlin et al., 2004; Singleton, 2003) have been
found in family pedigrees aﬀected by autosomal dominant, early onset
PD, although αS neurotoxicity contributes to both genetic and sporadic
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forms of PD (Shulman et al., 2011).
Aggregation of αS in insoluble inclusion is a complex nucleation
reaction that includes at least two key steps: the transition from an
unfolded monomer which has a naturally intrinsic unfolded con-
formation [(Burré et al., 2013; Chandra et al., 2003; Fauvet et al., 2012;
Theillet et al., 2016; Weinreb et al., 1996), although lately these data
have been questioned (Bartels et al., 2011; Dettmer et al., 2015; Wang
et al., 2011)] to an oligomer-type of structure and the transition to an
insoluble β-sheet rich protoﬁbril (Cremades et al., 2012; Deleersnijder
et al., 2013). Many variables are thought to inﬂuence these transitions:
point mutations, such as those associated with genetic PD (Conway
et al., 1998); C-terminal truncation (Li et al., 2005); protein level and
stability (Li, 2004); environmental factors (Uversky et al., 2002); post-
translational modiﬁcations, such as ubiquitination, phosphorylation,
nitration/oxidation (Oueslati et al., 2010).
Membrane interaction appears to be another condition that can
inﬂuence formation of αS ﬁbrils (H.-J. Lee et al., 2002). In fact, αS is
believed to shift between a free and a membrane-bound state in a dy-
namic equilibrium with the membrane-bound state accounting for
10–15% of the total protein amount. αS can bind synaptic vesicles and
its binding is believed to mediate its synaptic function (Burré, 2015). αS
has been implicated in a broad range of presynaptic functions that in-
cludes binding and promoting SNARE complex assembly to favor
docking of synaptic vesicles to the cell membrane (Burré et al., 2010,
2014), lipid transport and metabolism (Golovko et al., 2005, 2009),
neurotransmitters release and brain plasticity (Bendor et al., 2013).
Association with membranes is mediated by αS N-terminal seven 11-
amino-acids repeats that are predicted to form an amphipathic α-helix.
αS has been found to bind high-curvature membranes such as in pre-
synaptic vesicles, through the acquisition of a multimeric structure with
a deﬁned orientation (Burré et al., 2014). Thus, under normal condi-
tions αS can shuﬄe between a native unfolded structure to a multimeric
vesicle-bound conformation at the presynaptic terminals. However it is
not clear how the transition from these native conformations to a toxic
type of aggregates occurs.
We have recently described the presence of toxic αS high molecular
weight (HMW) species (oligomers and aggregates) associated with the
endoplasmic reticulum/microsomal vesicles (ER/M) in vivo, in diseased
Prp-A53T transgenic (Tg) mice (Colla et al., 2012a). αS HMW species
were sensitive to protease degradation suggesting that these αS species
were associated with the microsomal membrane on the cytosolic side.
Importantly, the appearance of αS oligomers at the ER/M level tem-
porally preceded the onset of neurodegeneration and ER stress-induced
cell death in a Tg mice, suggesting the microsomal membranes might be
a unique place to foster the accumulation of toxic species of αS (Colla
et al., 2012b).
In this paper we took a deeper look into the ER/M-associated αS
HMW species, comparing them to the rest of αS aggregates puriﬁed
through low speed centrifugation. Our ﬁndings provide evidence of the
existence of a toxic species of αS in vivo, associated with the ER/M
vesicles that has unique biochemical traits and is more aggressive in
spreading and inducing cell death in neuronal primary cultures.
2. Materials and methods
2.1. Animal models
Transgenic mice expressing human A53T αS under the control of the
mouse prion protein (PrP) promoter [line G2-3(A53T)] have been de-
scribed previously (Colla et al., 2012a, 2012b; M. K. Lee et al., 2002; Li
et al., 2005; Martin et al., 2006). This model develops fatal neurological
disease at ~12 months of age which rapidly progresses to end state
within 14–21 days of onset. Diseased mice show a drastic reduction in
motor function, accumulation of intracellular αS inclusions and neu-
ronal death. For this study, sick mice at 12–14 months of age, pre-
symptomatic mice at 9 months and age-matched nTg littermates were
used. Presymptomatic animals did not show any motor dysfunction or
αS pathology in the central nervous system. All animal studies were
approved and complied in full by the national and international laws
for laboratory animal welfare and experimentation (EEC council di-
rective 86/609, 12 December 1987 and Directive 2010/63/EU, 22
September 2010).
2.2. Membrane fractions preparation
Membrane pellet fractions were obtained as previously described
(Colla et al., 2012a). Brieﬂy, fresh tissues were homogenized in a 1:10
(wt/vol) volume of lysis buﬀer (250 mM sucrose, 20 mM HEPES,
10 mM KCl, 1.5 mM MgCl2, 2 mM EDTA, protease and phosphate-in-
hibitors cocktails) using a Teﬂon pestle homogenizer. Initial homo-
genates were centrifuged at 1000 ×g to remove nuclei and unbroken
cells. The resulting supernatant was centrifuged at 10,000 ×g for
20 min at 4 °C to obtain the ﬁrst membrane pellet (called P10), while
the supernatant was centrifuged at 100,000 ×g for 1 hr at 4 °C to ob-
tain the microsomal pellet (called P100). Both pellet fractions were
washed with homogenization buﬀer once and centrifuged again at the
same speed as previously mentioned. P10 and P100 were then re-
suspended in 200 or 100 μl of lysis buﬀer, respectively, and their pro-
tein content was determined.
2.3. Western blot
Immunoblot and dot blot analyses were performed as previously
described (Colla et al., 2012a, b). The following antibodies were used:
syn1 (1:5000; BD Transduction Laboratories, Franklin Lakes, NJ);
LB509 (1:5000; Abcam, Cambridge, MA); mouse pser129-αS (1:1000;
DAKO, Glostrup, Denmark), syn303 (1:1000; Biolegend, San Diego,
CA); A11 (ThermoFisher Scientiﬁc, Eugene, OR). Quantitative analysis
of immune detected bands was done using ImageLab Software (Bio-rad,
Hercules, CA).
2.4. Primary hippocampal and cortical neurons preparation and P10 and
P100 fractions treatment
Primary neuronal cultures were prepared from wild-type (WT)
newborn (P0) hippocampus and cortex of mouse strain B6.129, ac-
cording to a procedure by Beaudoin et al., (2012). Hank's Balanced Salt
Solution was used as mechanical dissection medium. Tissues me-
chanically dissected were treated with 0.1% trypsin for 7 min at 37 °C
and then collected with regular DMEM medium containing fetal bovine
serum (FBS) and DNase. Preparations were centrifuged at 1000 rpm for
5 min and pellet was resuspended in Neurobasal medium containing
2% B27, 1X Glutamax, 6 mg/ml glucose, 10% FBS, 12.5 μM glutamate
and 1X Gentamicin. Dissociated neurons were plated on poly-D-lysine
coated coverslips placed in 24 well dishes at a concentration of about
100,000 cells/cm2. At day in vitro (DIV) 1 the medium was replaced
with new fresh Neurobasal medium containing 2% B27, 1X gentamicin
and 1X Glutamax. At DIV2, 1/3 of the medium was removed and re-
placed with fresh medium containing 2.5 μM cytosine arabinoside for
48 hrs to reduce glial contamination.
Neurons were treated at DIV7 with 0.5, 1 or 2 μg of various pellet
fractions according to the experiment. To avoid sample variability, 4–5
pellet fractions isolated from diﬀerent mice with the same phenotype
were pooled. For internalization experiments, neurons were ﬁxed after
2 days, 1 week or 2 weeks of treatment.
2.5. Cell lines
Human neuroblastoma SH-SY5Y cells were transfected with a
pcDNA3.1 plasmid carrying human WT αS cDNA tagged at the C-
terminal with Myc. Cells stably carrying the plasmid were kept poly-
clonal and routinely cultured in DMEM medium containing 10% FBS,
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1% penicillin/streptomycin and 500 μg/ml of G418 as selection anti-
biotic.
For pellet fractions treatment, 50,000 cells/well were plated on
poly-D-lysine coated coverslips placed in 24 well dishes. The day after,
pellet treatment was done following the same protocol described for
neurons except that, in case of SH-αS-Myc WT, 5 μg of various mem-
brane fractions were added. Cells were ﬁxed after 2 days of treatment.
2.6. Confocal immunoﬂuorescence
Cells were ﬁxed with 2% paraformaldehyde and 5% sucrose solu-
tions for 15 min at room temperature (RT) and permeabilized with
0.3% Triton x-100 (Tx-100). Standard immunoﬂuorescence was per-
formed as previously described (Colla et al., 2012a). The following
antibodies were used: syn1 (1:2500), rabbit pser129-αS (EP1536Y,
1:1000, Abcam, Cambridge, MA), Map2 (1:10000, Abcam) and Lamp1
(1:1000, Abcam), NeuN (1:1000 Millipore, Merck, Darmstadt, Ger-
many); syn303 (1:1000), Tau (1:10000 Synaptic system, Goettingen,
Germany), mouse αS (1:200 Cell Signal, Leiden, The Netherlands).
Quantitative analysis of total ﬂuorescence, after background sub-
traction or particles count per ﬁeld was done using Image J software.
For the “two-stages” immunoﬂuorescence, live cultures were in-
cubated before ﬁxation with 3% FBS for 30 min at 4 °C with gentle
rocking and then incubated with primary antibody dissolved in 3% FBS
for 30 min at 4 °C. Cells were then washed, ﬁxed and stained following
the standard procedure. Stacked images were acquired with a laser
scanning confocal microscope SP2 system (Leica Microsystems) using a
63× objective.
2.7. Tunel staining
After ﬁxation, neuronal cultures were incubated with 1X Terminal
Deoxynucleotidyl Transferase (TdT) Buﬀer (3 mM trizma base, 14 mM
cacodylate sodium, 0.1 mM cobalt chloride, pH 7.2) for 15 min at 37 °C
and subsequently with TdT reaction mixture containing TdT buﬀer,
1 mM Biotin-16-dUTP, 400 U/μl terminal deoxynucleotidyl transferase
[Roche, Indianapolis, IN] for 1 hr at 37 °C. After incubation, the enzyme
activity was blocked by washing with 2X Saline‑sodium citrate (SSC).
Unspeciﬁc binding sites were blocked by incubating for 30 min with a
blocking solution containing 1% BSA and 0.1% Tx-100 at RT. Neurons
were incubated with 1:3000 Streptavidin Alexa Fluor® 568 conjugate
(ThermoFisher Scientiﬁc), for 1 hr at RT in the dark. After incubation,
neurons were washed repeatedly with PBS and standard immuno-
ﬂuorescence protocol for NeuN antibody and DAPI staining was carried
out.
Pictures were taken using Nikon Eclipse E600 epi-ﬂuorescence mi-
croscope (Nikon Corp, Tokyo, Japan) with 20× objective. Cell
counting was done using ImageJ software (National Institute of Health).
2.8. Immunodepletion
Immunodepletion of αS species was performed by incubating 20 μg
of P100 fractions (pooled from 4 mice) obtained from SpC of diseased
and presymptomatic animals, with 500 ng of A11, Syn1 or Syn303
antibodies previously conjugated with protein A/G agarose
(ThermoFisher Scientiﬁc). After 1 hr incubation at 4 °C, samples were
centrifuged at low speed (2500 rpm for 5 min) to remove im-
munoprecipitated complex conjugated with the agarose. The super-
natant that represented the immunodepleted sample was carefully re-
moved, avoiding any agarose contamination. 2 μg of each sample was
then loaded on a denaturing SDS Page and immunoblotted with Syn1
antibody to check for αS levels. According to the experiment 1 or 2 μg
was then administered to neuronal cultures.
2.9. Statistical analysis
All values are expressed as the mean ± SD. Diﬀerences between
means were analyzed using Student's t-test and one-way ANOVA fol-
lowed by Tukey multiple comparisons test (Prism, Graph Pad Software,
LaJolla CA).
3. Results
3.1. Biochemical characterization of αS aggregates
Because we recently identiﬁed αS oligomers and aggregates asso-
ciated with the ER/M membrane in presymptomatic and diseased
transgenic mice (Colla et al., 2012a, b), we decided to focus on the
biochemical and functional characterization of these aggregates to
understand whether distinct populations of αS HMW species exist at the
same time in neurons. To do this we isolated all the αS HMW species
from a disease-aﬀected area such as the spinal cord (SpC) of sick A53T
transgenic (Tg) mice and separated them into two diﬀerent populations
according to their sedimentation rate. These populations were named
P10 and P100. P10 represents a crude membrane pellet fraction that
sediments at 10,000 ×g, containing the majority of αS aggregated
species (M. K. Lee et al., 2002; Li et al., 2005) and is rich in mi-
tochondria and synaptosomes. P100 is the microsomal pellet, a fraction
that sediments at 100,000 ×g and is rich in ER, Golgi and synaptic
vesicles. According to this protocol, there are virtually no aggregates
that remain in the cytosol after centrifugation (Colla et al., 2012a). In
order to correlate changes in αS compositions in diﬀerent fractions to
the onset of αS-driven pathology, P10 and P100 fractions were also
obtained from SpC of presymptomatic (aged 9 months) mice and from
pathology-free regions like cortex (Ctx) of diseased age-matched lit-
termates.
Since C- and N-terminal truncations of the αS protein are thought to
be involved with aggregation and neuronal toxicity (Li et al., 2005), we
mapped the accumulation of truncated species in P10 and P100 using
an antibody raised against the central portion of the protein, the NAC
domain (Syn1 clone 42). Analysis of truncation showed how accumu-
lation of the most abundant truncated fragments Syn12, Syn10 and
Syn8 changed with disease onset within the two aggregates populations
(Fig. 1). In presymptomatic mice, increased accumulation of Syn12, the
most abundant and normally occurring C-terminal truncated fragment
(Li et al., 2005), was only found in P10. With disease onset, however,
the whole truncation pattern dramatically changed and P100 showed
increased protein truncation compared to P10, with an elevated accu-
mulation of all the truncated fragments analyzed, including Syn8, the
aggregation-speciﬁc N- and C-terminal truncated specie. Analysis of Ctx
from diseased mice, a region not aﬀected by αS pathology in this mouse
model, showed a puzzling truncation pattern with a decreased accu-
mulation of Syn12 in P100 and concomitant increased of Syn10. No
Syn8 accumulation was found in presymptomatic or Ctx from diseased
mice conﬁrming lack of aggregation in these two areas.
Thus the αS species associated with P100 show an increase in αS
truncation compared to P10 that is temporally and spatially linked to
the disease onset and concurrent with αS aggregation.
Since western blot analysis showed diﬀerences in the content of αS
HMW bands between P10 and P100 from sick SpC, we determined the
amount of αS oligomers and aggregates accumulated within the pellet
fractions using speciﬁc markers of aggregation such as syn303 anti-
body, speciﬁc for oxidized/aggregated αS and A11, speciﬁc for oli-
gomer species. Dotblot analysis conﬁrmed previous data that only af-
fected tissues in diseased mice accumulated aggregated αS
(Supplemental Fig. 1), although P100 immunoreactivity to syn303 was
signiﬁcantly higher than in P10. Moreover P100 from sick SpC con-
tained more αS oligomers compared with P10 as detected by the A11
that were also present in some of the P100 fractions of presymptomatic
mice and more phosphorylated αS at serine 129, compared to P10, with
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speciﬁc accumulation of phosphorylated HMW bands. Analysis of Ctx of
diseased mice showed a slight increase in oligomers/aggregates and
phosphorylated αS in P100, with respect to P10, although much less
abundant than in aﬀected SpC, suggesting that early signs of αS ag-
gregation appear initially in the P100/M fraction.
Taken together these results suggest that speciﬁc features such as
increased aggregation, truncation and phosphorylation can deﬁne a
distinctive specie of αS associated with the P100/M vesicles.
3.2. Spreading of αS aggregate fractions in mouse primary hippocampal and
cortical neurons
In order to understand whether αS species present in P10 and P100
fractions induce toxicity to neurons, we added P10 and P100 fractions
isolated from presymptomatic (SpC) and diseased mice (SpC or Ctx) in
the conditioned medium of hippocampal or cortical primary neurons
obtained from WT mice. To avoid sample variability, P10 or P100 were
obtained by pooling fractions puriﬁed from 3 to 4 age-matched mice of
the same condition.
Application of 1 μg of P100 fraction from sick mice to neuronal
cultures resulted in the appearance of long strings of beads-like struc-
tures after two weeks of treatment, that were positive for αS aggregates
speciﬁc antibodies such as pSer129-αS [Fig. 2 A, E(c)] and syn303
[Fig. 2 D, E (a,b)] and organized in a neurite-like pattern. Partial co-
localization with neuronal synaptic and axonal markers such as mouse
αS and Tau conﬁrmed that these structures made of αS aggregates were
indeed associated with the neurites network (Fig. 2C). Occasionally
these strings appeared to co-localize and stain the cell soma or cover the
entire process, resembling necrotic neurites. In this latter case when
cultures where stained with the neuronal marker syn1, the neurites
network appeared to be less dense and more scattered when treated
with P100 from sick mice, especially for cortical cultures, suggesting
that the formation of these strings of αS aggregates might be detri-
mental for cells. While for P100 those structures were more abundant
and covered the neuronal network extensively, administration of the
same amount of P10 produced very few small and scattered strings that
were more immature in size and number (Fig. 2). No major diﬀerences
were detected in the formation of these strings of aggregates between
hippocampal and cortical neurons (Fig. 2D). Further administration of
P10 and P100 from presymptomatic mice or P100 from Ctx of sick mice
or nTg littermates failed to produce any string-like structure positive for
syn303 (Supplemental Fig. 2) or pSer129-αS (data not shown).
Formation of αS positive strings were also dose- and time-dependent
since reducing by half (0.5 μg) the original dose of P100 fraction from
SpC of sick mice or ﬁxing neuronal cultures at earlier time points re-
sulted in few scattered ﬁbrillary structures or numerous premature
puncta that while their amount increased over time, failed to form an
elongated and complete string (Supplemental Fig. 3A,C) when analyzed
at early time points. In both cases administration of P10 from sick mice
failed to produce comparable string-like structures positive for syn303
or pSer129-αS.
To understand whether these strings of αS aggregates accumulated
endogenously or were externally attached to the plasma membrane we
used a protocol of “two-stage” immunoﬂuorescence where labeling of
P100-associated aggregates with pSer129-αS antibody was done in
living neurons, before ﬁxation and permeabilization. In this case the
Fig. 1. Accumulation of αS truncated fragments in P10 and P100 pellet fractions.
A, B, C, Immunoblotting showing how neurodegeneration aﬀects the levels of αS truncated fragments in P10 and P100 fractions obtained from SpC of presymptomatic (PreS) (A) or sick
Ctx (B) and SpC (C) of A53T Tg mice. 2 μg of each fractions was run on a denaturating SDS-Page, transferred and blotted with syn1 antibody that recognizes the most abundant truncated
fragments, Syn12, Syn10, Syn8 and HMW species (arrows heads) of αS. Human αS monomer was visualized with human speciﬁc antibody LB509. FL, αS full length monomer. D, E, High
exposure images of immunoblots in B and C, respectively, to better visualize accumulation of truncated fragments Syn10 and Syn8 in P100. F, G, H, Quantitative analysis of relative
density of αS truncated fragments in P10 and P100 respectively in PreS, sick Ctx or SpC, obtained by normalization with human αS full length monomer detected with LB509. Values are
expressed as % of P10 and are given as the mean ± SD (n= 3 or 4). *p < 0.05, **p < 0.001, Student's t-test.
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plasma membrane remains intact so only αS species that are not in-
ternalized by the neurons can be labeled. After incubation with the
pSer129-αS antibody, cultures were extensively washed and then ﬁxed,
permeabilized and stained with the syn303 antibody in order to label
all the aggregates, inside and outside the cell membrane. Surprisingly,
all the P100 aggregates were labeled only with syn303 but not with
pSer129-αS, indicating that P100-associated αS species are contained
within the neurons and not merely externally attached to the cell
membrane (Fig. 3b). The lack of merged signal between syn303 and
pSer129-αS also suggested that an active transport in living cells of
membrane-bound antibodies was not signiﬁcant in our conditions.
Switching the antibody used in live neurons, i.e. incubating live primary
cultures with syn303 and then staining with pSer129-αS antibody, did
not aﬀect the outcome of the two-stage immunoﬂuorescence
Fig. 2. Treatment with P100 fractions induced de-
position of beads-like structures made of αS ag-
gregates in primary murine neurons.
Formation of beads-like structures made of αS ag-
gregates after administration of 1 μg of P10 or P100
fractions pooled from 3 to 4 SpC of sick mice to hip-
pocampal [A, B (a,b)], or cortical primary neuronal
cultures [B (c,d), C]. Cultures were ﬁxed after 2 weeks
of treatment and stained with pSer129-αS or Syn303
antibodies. A, Representative immunoﬂuorescence
images showing αS-positive strings after P10 and P100
treatment in hippocampal cultures stained with the
pSer129-αS antibody. P100 administration induced
deposition of beads-like structures organized in a
string and following a neurite-like pattern. These
strings were positive for αS aggregates speciﬁc anti-
bodies such as pSer129-αS. Compared to P100, P10
treatment induced the formation of small puncta that
resembled those obtained for P100 but were less
abundant and more immature in size and number.
Images were taken with Nikon Eclipse E600 epi-
ﬂuorescence microscope using a 20× objective. Scale
bar = 100 μm. B, C, Quantitative analysis of images in
A showing increased accumulation of pSer129-αS po-
sitive structures in P100 treated cultures. Fluorescence
signal was measured as total ﬂuorescence after back-
ground subtraction (B) or as particles count (C) using
Image J software. Both parameters were normalized
with the total nuclei count (labeled with DAPI) per
ﬁeld. Values are expressed as % of P10 and are given
as the mean ± SD (n= 6). ***p < 0.0001, Student's
t-test. D, Confocal images showing that no major dif-
ference between hippocampal (a,b) or cortical (c,d)
cultures were detected in the formation of αS-positive
strings after administration of P10 or P100 obtained
from SpC of sick mice. Occasionally αS strings after
P100 treatment appear to cover the entire process,
resembling necrotic neurites (b, d). To check the
neuronal viability, cultures were also stained with
syn1 antibody (red). Stacked images were acquired
with a Leica confocal microscope SP2 system using a
63× objective. Scale bar = 50 μm. E, Confocal
images showing partial co-localization with neuronal
markers such as mouse αS (mαS) (a,b) and Tau (c) in
cortical primary cultures treated with P100 fractions
from SpC of diseased mice. Occasionally these strings
positive for αS aggregates co-localize and stain the cell
soma (a and b arrow heads). Stacked images were
acquired using a 63× objective. Scale bar = 50 μm
(a), 20 μm (b,c).
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experiment, since no syn303 staining was detected without permeabi-
lization (Supplemental Fig. 4A). However, when neurons were ﬁxed
before the incubation with pSer129-αS and syn303, αS strings were
mostly co-labeled by both antibodies, especially in the case of larger
puncta, ruling out the possibility that competition for the same target
could interfere with the aggregates staining by both antibodies at the
same time. To conﬁrm that αS aggregates that are externally associated
with the cell membrane can be eﬃciently labeled following the “two-
stage” immunoﬂuorescence protocol we repeated this assay using
neuroblastoma cell lines (SH-SY5Y) stably expressing WT αS tagged
with Myc. When the P100 fraction was given to these cells and “two
stage” immunoﬂuorescence was performed, most of the aggregates
were double labeled with pSer129-αS and syn303 antibodies, showing
that most of the aggregates were found associated outside the cell
membrane. Additionally, incubation of live neuronal cultures treated
with buﬀer (B) with Map2 (Fig. 3a) or grp94 antibodies and SH-αS-Myc
WT cells treated with grp94, according to the “two-stage” immuno-
ﬂuorescence protocol (Supplemental Fig. 4B) did not result in any
staining unless cells were previously ﬁxed, conﬁrming that no anti-
bodies can label cellular endogenous targets without previous ﬁxation
and permeabilization of the cellular membrane as done in our experi-
mental settings. Moreover since the endosomal-lysosomal pathway has
been implicated in the internalization of exogenous in vitro preformed
αS ﬁbrils (Karpowicz et al., 2017), double staining with syn303 and
Lamp1, a lysosomal marker, was done in cortical neuronal culture after
2 days or 1 week of treatment with P100 fractions from SpC of sick Tg
mice. We found little co-localization between syn303 and Lamp1 at
both times, suggesting that the endosomal pathway might not be the
preferential route of entry of P100-associated aggregates in primary
neurons (Supplemental Fig. 5).
In summary, treatment with P100 fractions from diseased mice that
contain microsomal-associated αS species induced the formation of
string-like structures, positive for αS aggregates speciﬁc antibodies, that
followed a neurite pattern and co-localized with synaptic and axonal
markers.
3.3. Induction of apoptosis in mouse hippocampal and cortical primary
culture treated with P100 from SpC of presymptomatic and diseased mice
Increasing the concentration of the above fractions to 2 μg resulted
in induction of apoptosis only in primary cultures treated with P100
fractions obtained from SpC of diseased mice and more surprisingly
from presymptomatic littermates, as shown by the increase in TUNEL
staining and the concomitant decrease of neuronal survival measured
by NeuN labeling (Fig. 4). No neuronal degeneration in cultures treated
with P10 from sick and presymptomatic mice, P100 Ctx or P100 nTg
was observed. Although TUNEL levels were comparable between pre-
symptomatic and sick P100 fractions, the NeuN-positive count was
actually higher in presymptomatic P100-treated samples, suggesting
that αS species associated with microsomal fractions obtained from
healthy aged animals were less aggressive in inducing cellular death. In
the ﬁrst experiments, although early signs of cellular death were visible
Fig. 3. Internalization and spreading of P100 fractions
into neuronal cultures.
Two-stage immunoﬂuorescence showed how αS ag-
gregates spread into within the neurons to form αS
positive strings. Live hippocampal neurons treated
with buﬀer (B) (a), P100 fractions from sick SpC (b) or
SH-SY5Y neuroblastoma cells stable for αS expression
(SH-αS-Myc WT) treated with 5 μg of P100 sick SpC
(d) were incubated at 4 °C with Map2 or pSer129-αS
antibody, for 30 min before being ﬁxed, permeabilized
and stained with mαS or syn303 antibody, respec-
tively. Confocal stacked images were acquired with a
63× objective. Absence of merged signals showed
that no antibodies can label endogenous target
without previous ﬁxing and permeabilization of the
cell membrane indicating that most of the αS ag-
gregates are internalized by neurons. When neurons
treated with P100 sick SpC were instead ﬁxed (c) be-
fore pSer129-αS and syn303 incubation, both anti-
bodies label αS strings (arrow heads), although not
with the same eﬃciency. On the contrary, merged
signals between pSer129-αS and syn303 in SH-αS-Myc
WT treated with P100 pellet from Sick SpC (d, arrow
heads) demonstrated that αS aggregates are not in-
ternalized in this cell model. Thus only in the case of
αS aggregates externally attached to the neurite
membrane or the cell membrane being permeabilized,
both antibodies can co-label αS aggregates. In d) a
white line showing the cell borders was drawn by
overlapping ﬂuorescence with regular white light
images taken at the same time. Scale bar = 50 μm
(a,b,c), 20 μm (d).
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as soon as 24–48 hrs after addition, neurons were ﬁxed after 3 days of
treatment when neuronal degeneration in P100 sick treated cultures
became widespread. When we let the treatment go further and ﬁxed
cultures after a week, cell death was so exhausted in P100 sick-treated
neurons that very few cells (DAPI-positive nuclei) were left in the well.
In this case also neurons treated with P100 from presymptomatic mice
showed remarkable levels of cell death and neuronal loss, comparable
to what has been observed previously in cultures treated with P100 sick
and ﬁxed after 3 days (Supplemental Fig. 6). At the same time also
cultures treated with P10 from sick animals started to show a slight
decrease in NeuN-positive neuronal count and an increased in TUNEL
staining, showing that P10-associated αS aggregates can also be toxic
but not as aggressive as the P100 counterpart in inducing neuronal
death. Although TUNEL levels in sick P10-treated neurons were
comparable with the amount of cell death in cultures treated with
presymptomatic P100, the decrease in neuronal loss was not as re-
markable, suggesting that neuronal degeneration was delayed com-
pared to PreS-P100 treated cultures. Interestingly P10 from pre-
symptomatic mice was never able to induce apoptosis in primary
cultures in our experimental setting, while a mild decrease in neurons
viability was observed for P100 Ctx-treated cultures, although was not
signiﬁcant, for prolonged treatment. Thus, only microsomal fractions
obtained from diseased or presymptomatic aﬀected areas have an en-
hanced ability to induce cellular death in primary neuronal cultures
therefore are more toxic than P10. Interestingly, the only feature that
the P100 from presymptomatic and diseased areas have in common in
terms of αS structural or posttranslational modiﬁcations is the presence
of αS oligomers, suggesting that other modiﬁcations such as
Fig. 4. Induction of neuronal death in primary neurons after treatment with P10 and P100.
Primary hippocampal neurons were treated with 2 μg of various P10 and P100 pellet obtained from presymptomatic or diseased SpC and Ctx of Tg mice and age-matched Ntg littermates
or buﬀer (B). Cultures were ﬁxed after 3 days of treatment and co-labeled with NeuN and Tunel staining. Cultures were also counterstained with Dapi. A, Representative ﬂuorescent
images showing induction of apoptosis and concomitant decrease in neurons viability only in primary cultures treated with P100 fractions obtained from SpC of diseased mice and more
surprisingly from presymptomatic littermates. Fluorescent images were acquired with a Nikon epi-ﬂuorescence microscope using a 20× objective and cell counting was done using Image
J software. Scale bar = 100 μm. B, C, Quantitative analysis of images in the panel A for live NeuN-positive neurons (B) or dead Tunel-positive neurons (C). Live or dead cell counts were
normalized for the number of Dapi-positive nuclei. Values are expressed as % of control neurons treated with buﬀer and are given as the mean ± SD (n= 6). *p < 0.05, **p < 0.001,
***p < 0.0001, ****p < 0.00001, one-way ANOVA, followed by Tukey post-hoc test.
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Fig. 5. Immunodepletion of αS toxic species from
P100 prevents formation of αS strings.
To check if αS species associated with microsomes
were indeed responsible for cellular modiﬁcations
described above we perform immunodepletion of αS
species from the P100 fractions by incubating P100
with protein agarose conjugated with Syn1 (S1),
Syn303 (S303) or A11. A, Shows immunoblotting of
P100 immune-depleted (ID) fractions run along total
P100 pellets from presymptomatic (Tot P100 PreS) or
diseased mice (Tot P100 Sick). Samples were trans-
ferred to a nitrocellulose membrane and blotted with
Syn1 antibody. B, C, Quantitative analysis of αS full
length monomer (B) or HMW species (C) as shown in
A indicates a reduction in αS content for all species
after immunodepletion in P100 ID fractions.
Densitometric analysis of HMW bands was done by
measuring the relative intensity for the whole sample
lane above the monomer. Values are expressed as % of
corresponding total P100 pools, sick or presympto-
matic, and given as the mean ± SD (n= 3).
*p < 0.05, **p < 0.001 One-way ANOVA, followed
by Tukey post-hoc test. C, 1 μg of ID and original P100
samples from diseased were given to hippocampal
neurons. Cells were ﬁxed and immunostained with
syn303/mαS or pSer129-αS/Map2 after 2 weeks.
Stacked ﬂuorescent images taken at the confocal mi-
croscope showed a drastic decrease in the formation of
αS aggregates-positive strings. Scale bar = 50 μm.
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phosphorylation and truncation are not necessary for αS acquired
toxicity.
3.4. Partial depletion of the αS species from P100 fractions from diseased
and presymptomatic mice prevents spreading and induced toxicity in primary
cultures
To establish whether αS species contained in P100 fractions were
indeed responsible for the induction of apoptosis, immunodepletion
with various αS antibodies that recognize speciﬁc αS conformations
(A11 for αS oligomers, syn303 for αS aggregates and Syn1 for total αS)
was performed from pooled P100 fractions from SpC of diseased and
presymptomatic mice. Brieﬂy, P100 fractions were incubated with the
above antibodies, previously conjugated with protein-binding agarose,
for 1 hr at 4 °C. After spinning at low speed the supernatant was care-
fully recovered and checked for the content of αS species. αS monomer
and HMW species levels in immunodepleted (ID) samples were dra-
matically reduced to about 40–45% or 45–50%, respectively, of the
original total pools amount (Fig. 5 A, B, C). ID samples were then dosed
to cortical neuronal cultures and formation of αS strings and neuronal
death was evaluated. While neurons treated with P100 obtained from
SpC of sick mice developed αS aggregates-positive strings, cultures
treated with ID sick samples did not. More speciﬁcally, neurons treated
with ID Syn1 sick or ID A11 sick fractions showed scattered dot-like αS
structures not yet organized in a string pattern, more abundant in ID
A11 than ID Syn1, while ID syn303 sick-treated cultures showed only
very few small puncta positive for αS (Fig. 5C).
When we checked for toxicity, in the case of neurons treated with
P100 pooled from SpC of sick mice, cell death was already apparent
after 24–48 hrs of treatment. Nevertheless, to see if αS depletion could
eﬀectively rescue neurons, cultures were not ﬁxed immediately but the
treatment was continued to make sure that any possible rescuing eﬀect
that we would see was not due to a time frame diﬀerence. When cul-
tures were then analyzed for cell survival, neuronal degeneration in
P100 sick-treated cultures was exhaustive. In fact, the number of NeuN-
positive neurons (Fig. 6) had dramatically dropped only in samples
treated with P100 sick fractions but not in cultures treated with ID sick
fractions, suggesting that depletion of αS helped keep neurons healthy.
Interestingly immunodepletion of mature αS aggregates with syn303
was more eﬃcient in preventing αS-induced toxicity than the abroga-
tion of total αS in ID Syn1 samples, suggesting that toxicity is due to the
presence of αS HMW conformers rather than αS itself after disease
onset. Moreover while treatment with ID Syn1 and A11 seemed to only
delay cell death as shown by increased Tunel positivity compared to
P100 and control samples (Fig. 6C), immunodepletion with syn303
constitutively blocked apoptosis reducing Tunel level lower than un-
treated samples.
In the case of presymptomatic fractions, the number of NeuN-posi-
tive neurons was signiﬁcantly reduced only in cultures treated with
P100 PreS, but not in P100 PreS ID treated samples. Here im-
munodepletion with Syn 1 or A11 fully rescued neuronal cultures and
blocked cellular death as shown by reduced Tunel levels.
Thus reduced spreading of αS aggregates due to immunodepletion
prevents neuronal degeneration in murine primary neurons, indicating
that αS species contained in P100 pools are responsible for neurode-
generation after administration to primary neuronal cultures.
4. Discussion
The results presented here indicate that within the heterogeneity of
αS HMW species there is a small, unique fraction that is more ag-
gressive in terms of propagation and toxicity. This population of ex-
tremely toxic αS species is associated with the microsomal vesicles and
presents speciﬁc biochemical traits such as increased aggregation,
truncation and phosphorylation at serine 129 that makes them unique.
The hypothesis of an extremely detrimental factor or species within
the αS HMW population has been long postulated (Caughey and
Lansbury, 2003) and not only in PD but in other neurodegenerative
diseases as well (Ugalde et al., 2016). Initially questions arose regarding
the potential toxicity of αS oligomers as opposed to mature ﬁbrils to
explain, for example, early observations on why dopaminergic neurons
bearing LBs appeared to be healthier than neighboring neurons
(Tompkins and Hill, 1997). Since then a signiﬁcant body of evidence,
describing αS diﬀerent oligomer conformations in vitro and their asso-
ciated mechanism of toxicity has been generated (Roberts and Brown,
2015), despite that the in vivo presence of αS oligomers has been con-
troversial and particularly diﬃcult to characterize (Colla et al., 2012b).
On the opposite, more recent data (Luk et al., 2009, 2012; Volpicelli-
Daley et al., 2011) including an investigation led by V. Baekelandt
showed that both in vitro pre-formed oligomers and ﬁbrils are indeed
neurotoxic but display diﬀerent seeding capacity and induce diﬀerent
histopathological and behavioral abnormalities when injected in rats
(Peelaerts et al., 2015). Thus it appears that structure does not ne-
cessarily dictate toxicity, or at least in part, since both αS oligomers and
ﬁbrils seems to contribute to neuronal degeneration.
While most of the evidence accumulated until now to prove the
enhanced capacity of oligomers or aggregates to induce toxicity focused
on structural diﬀerences, in this paper, we took a diﬀerent approach
and we focused our attention on the diﬀerent subcellular location of αS
HMW species rather than their conformation.
By isolating αS HMW species from a Tg mouse model for αS ex-
pression, and separating them according to their molecular weight and/
or membrane-association, we showed how the ER/M-associated αS pool
is remarkably neurotoxic and able to seed formation of αS-positive
strings in primary neurons when compared to the rest of αS HMW
species that precipitates at low speed (P10). αS association and locali-
zation within the ER/M system in normal and diseased conditions has
been demonstrated in cultured cells, in neurons of Tg mice and PD brain
by biochemical isolation, cell imaging and electron microscopy (Colla
et al., 2012a, 2012b; H.-J. Lee et al., 2002; Lee et al., 2005). Given the
presynaptic localization of αS, its ability to bind to synaptic vesicles
through the SNARE complex and to inhibit the ER-Golgi transport
(Burre et al., 2010; Burré et al., 2014; Cooper et al., 2006; Thayanidhi
et al., 2010), it is not surprising to ﬁnd a weak association of αS with
microsomal vesicles, which is a raw pellet fraction containing ER, Golgi
e synaptic vesicles, in normal conditions (Colla et al., 2012a). Instead,
with αS aggregation and disease onset, the partitioning between
membranous-bound and free αS changes and there is an increased re-
distribution of αS to P100/M membranes (Colla et al., 2012a). This
could be due to an increase of αS protein stability and reduced turnover
correlated to change in conformation and protein solubility or to an
increased sequestration of free αS by aggregates. Interestingly, at the
presynaptic level, others have shown how free presynaptic αS can be
recruited into insoluble aggregates (Volpicelli-Daley et al., 2011) and
how presynaptic αS small aggregates might be more detrimental than
LB and correlate better with synapses dysfunction in vivo (Kramer and
Schulz-Schaeﬀer, 2007).
Association with the microsomal membrane seems to be very spe-
ciﬁc since although P10 contains membranous components that include
the mitochondria and MAM, we never found αS HMW species co-pre-
cipitating with this organelle when we puriﬁed mitochondria from af-
fected areas in the same mouse model (Colla et al., 2012b). In contrast,
we found a strong association between αS aggregates and the ER
membrane as shown by the ability of αS aggregates to ﬂoat and par-
tition with the membranous component on a lipid ﬂotation assay when
isolated as a P100/Microsomal pellet. Very interestingly when the
membranous component of P100 was removed by the addition of non-
ionic detergent and the lipid ﬂotation analysis was repeated, ER-asso-
ciated αS aggregates did not partition with the membrane fraction,
demonstrating that αS aggregates actively bind the ER/Microsomal
membrane (Colla et al., 2012a). In addition accumulation of αS pa-
thological changes such as formation of αS aggregates, truncation and
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phosphorylation are more likely to occur close to the ER/M membranes.
Similarly because of this association it is also plausible that in patho-
physiological conditions the ﬁrst changes implicated in αS acquired
toxicity occur at the ER/M membranes level. Thus association with the
microsomal membranes seems to be a key step for αS acquired toxicity.
Although it remains unclear what is the pathological role of all the
changes associated with neurotoxicity that αS undergoes, the cortical
region in Prp A53T mice may be a good model to study early changes in
αS toxic modiﬁcations. In fact, although the cortical regions in Prp
A53T mice have no overt accumulation of αS aggregates and LB-like
inclusions, nor neuronal degeneration or gliosis (M. K. Lee et al., 2002),
the P100 fractions obtained from Ctx of sick mice did show mild early
changes in protein truncation, phosphorylation or accumulation of αS
oligomers/aggregates that may resemble an intermediate condition
between presymptomatic and disease. At the same time P100 Ctx
fraction did not signiﬁcantly induce cell death when given to primary
cultures, indicating these initial changes in αS are not suﬃcient to in-
duce an overt neuronal degeneration.
Once administered to primary neurons, P100/M-associated αS toxic
species from diseased mice quickly spread into neurons in a similar
manner to what has been described by V. Lee and coworkers (Volpicelli-
Daley et al., 2011, 2014). In their work, in vitro assembled αS ﬁbrils
initially induced the deposition of strings of small puncta within
neurites, resembling what we obtained when low amount of P100 Sick
SpC was used or when neuronal cultures were ﬁxed at early time points
(Supplemental Fig. 3), which subsequently developed into ﬁbrous
structures covering processes and soma. Although we only occasionally
saw accumulation of ﬁbrous strings in the neuronal cell body, probably
because of the diﬃculty in ﬁnely adjusting the titration of P10 and
P100 fractions in our cultures, the ﬁbrous structures described by
Volpicelli-Daley's paper are comparable to what we obtained by
treating neurons with increasing concentration of P100/M fractions
Fig. 6. Immunodepletion of αS toxic species from P100 prevents neurodegeneration in murine primary cultures.
2 μg of ID and total P100 samples from diseased and presymptomatic mice or buﬀer (B) were administered to hippocampal neurons in culture. A, Representative images of im-
munostaining with NeuN antibody or Tunel shows an increase in cell survival and concomitant reduction in neuronal death in cultures treated with ID samples obtained from pre-
symptomatic and sick mice. Fluorescent images were acquired with a Nikon epi-ﬂuorescence microscope using a 20× objective. Scale bar = 100 μm. B, C, Cell survival graph of NeuN-
positive neurons (B) or Tunel staining (C) after administration of ID and total fractions showed how reduction in P100-associated αS toxic species prevents cell death. Values were
normalized for the number Dapi-positive nuclei and expressed as % of neurons treated with buﬀer. In the graph each column represents the mean ± SD (n= 6). *p < 0.05,
**p < 0.001, ***p < 0.0001, ****p < 0.00001, One-way ANOVA, followed by Tukey post-hoc test.
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from Sick SpC. In addition the dose- and time-dependent formation of
αS ﬁbrous strings and their co-localization with mouse endogenous αS
may suggest that mouse αS could become entangled and recruited into
these bead-like structures, similarly to what have been previously de-
scribed after administration of in vitro preformed αS ﬁbrils (Volpicelli-
Daley et al., 2011). However, since the co-localization with mouse αS
was only partial, it is unlikely that the formation of αS strings in cul-
tured neurons is only due to aggregated mouse αS. In the same way the
limited co-localization between Tau and αS strings suggested a lower
chance for Tau to cross-seeds αS aggregates deposition after P100 ad-
ministration.
In terms of amount of cell toxicity of P100/M fractions from sick
SpC was far more detrimental than what V. Lee's paper suggested
(Volpicelli-Daley et al., 2011), considering that the dosage we used was
lower and far less concentrated. Thus, a small amount of P100/M-as-
sociated αS was suﬃcient to induce a massive apoptotic response in
primary neurons (Figs. 4, 6). Levels of cell death in neurons treated with
P100 PreS were remarkably higher than with P10 Sick, indicating that
before accumulation of αS oligomers/aggregates and aggregation-re-
lated modiﬁcations, some toxic αS species associated with the micro-
somal membrane were already present. Despite that, we were never
able to observe deposition of any αS puncta or string in presympto-
matic-treated cultures with aggregates-speciﬁc antibodies (syn303 or
pSer129-αS) or with a human αS antibody, conﬁrming that soluble
toxic forms of αS have diﬀerent seeding properties from ﬁbrils
(Peelaerts et al., 2015) and that αS oligomers do not need to become
mature aggregates to be toxic. Also because of the toxicity of αS asso-
ciated with P100 PreS, it appears that accumulation of truncated and/
or phosphorylated species is only secondary and does not account for
the acquired ability to induce neuronal death. Moreover, im-
munodepletion experiments showed how the toxic function of αS de-
pends on its internalization and propagation rather than a mere acti-
vation of a cell death cascade from the cell membrane. In fact treatment
with P100 ID samples prevented induction of neuronal death and a
correspondent striking reduction in the formation of αS-positive
neuritic strings (Figs. 5, 6). Thus our data point to a change in structure
and a speciﬁc interaction with the ER/M, shown by the abundant
presence of soluble αS oligomers in the P100/M fractions of diseased
and presymptomatic mice (Supplemental Fig. 1 and (Colla et al.,
2012b) as the main culprit of αS propagation and neuronal degenera-
tion.
5. Conclusions
Our results have demonstrated the in vivo existence of a toxic pool of
αS HMW species associated with the ER/M vesicles. Our data suggests
that the ﬁrst pathological changes in αS behavior appear in the small
portion of αS associated with the microsomal vesicles, (probably at a
presynaptic level). It is not yet clear whether other αS aggregates (that
we concentrated in P10) derived from the microsomes-associated pool
or form independently. While more studies will be necessary, our
ﬁndings provide the ﬁrst insights in the pathological behavior of αS in
vivo, shining a critical spotlight on the association with the P100/M
membranes as a necessary step toward the acquisition of αS toxicity.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2017.12.004.
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